Table 3

Systemic administration of FGF2-AdTK and AdTK in the B16F10 lung metastasis model

TreatmentNo. of pulmonary metastasesa mean ± SERange
Vehicle and GCV43 ± 5.815–68
FGF2-AdTK and NaCl44 ± 5.024–60
FGF2-AdTK and GCV15 ± 7.0b0–46
  • a n = 8/group.

  • b P H 0.005 compared with Vehicle and GCV or FGF2-AdTK and NaCl (ANOVA and Fisher’s PLSD post hoc analysis).